Abstract
Systemic therapy and subsequent survival for patients with extensive-stage small-cell lung cancer (SCLC) are poor and have remained unchanged in the past quarter century. To improve outcomes in these patients, a new drug development paradigm must be adopted that moves away from empiricism and instead focuses on tumor biology and heterogeneity as a means to increase target and drug class diversity. By incorporating tools that have led to new diagnostic and treatment options in non-small-cell lung cancer, there could be hope yet for the future of SCLC therapeutics.
Original language | English (US) |
---|---|
Pages (from-to) | 93-95 |
Number of pages | 3 |
Journal | Clinical Lung Cancer |
Volume | 15 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2014 |
Keywords
- Amrubicin
- Chemotherapy
- Clinical trials
- Developmental therapeutics
- Small cell lung cancer
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Pulmonary and Respiratory Medicine